423 related articles for article (PubMed ID: 31075543)
1. Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review.
Chen H; Laba JM; Zayed S; Boldt RG; Palma DA; Louie AV
J Thorac Oncol; 2019 Aug; 14(8):1332-1342. PubMed ID: 31075543
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy for Ultra-Central lung Tumors: A systematic review and Meta-Analysis and International Stereotactic Radiosurgery Society practice guidelines.
Yan M; Louie AV; Kotecha R; Ashfaq Ahmed M; Zhang Z; Guckenberger M; Kim MS; Lo SS; Scorsetti M; Tree AC; Sahgal A; Slotman BJ
Lung Cancer; 2023 Aug; 182():107281. PubMed ID: 37393758
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic ablative radiotherapy for malignant mediastinal and hilar lymphadenopathy: a systematic review.
Tjong MC; Malik NH; Chen H; Boldt RG; Li G; Cheung P; Poon I; Ung YC; Tsao M; Louie AV
J Thorac Dis; 2020 May; 12(5):2280-2287. PubMed ID: 32642133
[TBL] [Abstract][Full Text] [Related]
5. Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumours Treated by Intensity-Modulated Radiotherapy-Based Stereotactic Ablative Body Radiotherapy With Homogenous Dose Prescription.
Mihai AM; Armstrong PJ; Hickey D; Milano MT; Dunne M; Healy K; Thirion P; Heron DE; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 Oct; 33(10):627-637. PubMed ID: 34092462
[TBL] [Abstract][Full Text] [Related]
6. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.
Chaudhuri AA; Tang C; Binkley MS; Jin M; Wynne JF; von Eyben R; Hara WY; Trakul N; Loo BW; Diehn M
Lung Cancer; 2015 Jul; 89(1):50-6. PubMed ID: 25997421
[TBL] [Abstract][Full Text] [Related]
8. Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial.
Palma DA; Chen H; Bahig H; Gaede S; Harrow S; Laba JM; Qu XM; Rodrigues GB; Yaremko BP; Yu E; Louie AV; Dhaliwal I; Ryerson CJ
BMC Cancer; 2019 Dec; 19(1):1206. PubMed ID: 31829203
[TBL] [Abstract][Full Text] [Related]
9. Risk-adapted stereotactic ablative radiotherapy for central and ultra-central lung tumours.
Lenglet A; Campeau MP; Mathieu D; Bahig H; Lambert L; Vu T; Roberge D; Bilodeau L; Filion E
Radiother Oncol; 2019 May; 134():178-184. PubMed ID: 31005213
[TBL] [Abstract][Full Text] [Related]
10. Comparing the Outcomes of Stereotactic Ablative Radiotherapy and Non-Stereotactic Ablative Radiotherapy Definitive Radiotherapy Approaches to Thoracic Malignancy: A Systematic Review and Meta-Analysis.
Hegi F; D'Souza M; Azzi M; De Ruysscher D
Clin Lung Cancer; 2018 May; 19(3):199-212. PubMed ID: 29370978
[TBL] [Abstract][Full Text] [Related]
11. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy.
Zhao L; Zhou S; Balter P; Shen C; Gomez DR; Welsh JD; Lin SH; Chang JY
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1226-35. PubMed ID: 27209498
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic Body Radiotherapy Reirradiation Is Safe in Patients With Lung Cancer With In-Field Enlarged Tumor Recurrence.
Berber T; Yıldırım BA; Kandemir Gürsel Ö
Technol Cancer Res Treat; 2024; 23():15330338231208616. PubMed ID: 38860536
[No Abstract] [Full Text] [Related]
14. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic ablative radiation therapy versus conventionally fractionated radiation therapy for stage I small cell lung cancer.
Verma V; Hasan S; Wegner RE; Abel S; Colonias A
Radiother Oncol; 2019 Feb; 131():145-149. PubMed ID: 30773182
[TBL] [Abstract][Full Text] [Related]
16. Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-small Cell Lung Cancers Using 50 Gy in Five Fractions.
Rulach R; McLoone P; Lumsden G; McKay S; MacLaren V; Macphee J; Moore K; Omand M; Sproule M; Currie S; Aitken A; Ferguson R; Valentine R; Houston P; Harrow S; Hicks J
Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):250-258. PubMed ID: 31607611
[TBL] [Abstract][Full Text] [Related]
17. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
[TBL] [Abstract][Full Text] [Related]
18. Long-term toxicity and survival outcomes after stereotactic ablative radiotherapy for patients with centrally located thoracic tumors.
Atalar B; Mustafayev TZ; Sio TT; Sahin B; Gungor G; Aydın G; Yapici B; Ozyar E
Radiol Oncol; 2020 Jun; 54(4):480-487. PubMed ID: 32589607
[TBL] [Abstract][Full Text] [Related]
19. Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer.
Meng MB; Wang HH; Zaorsky NG; Sun BS; Zhu L; Song YC; Li FT; Dong Y; Wang JS; Chen HM; Yu XY; Yuan ZY
Cancer Sci; 2019 Nov; 110(11):3553-3564. PubMed ID: 31464032
[TBL] [Abstract][Full Text] [Related]
20. Ultra-central Thoracic Re-irradiation Using 10-fraction Stereotactic Body Radiotherapy for Recurrent Non-small-cell Lung Cancer Tumors: Preliminary Toxicity and Efficacy Outcomes.
Sood S; Ganju R; Shen X; Napel MT; Wang F
Clin Lung Cancer; 2021 May; 22(3):e301-e312. PubMed ID: 33132058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
